• Emergent BioSolutions won Saudi Food and Drug Authority registration for ACAM2000, a live vaccinia vaccine for prevention of smallpox and mpox in people deemed at high risk.
• The clearance marks the company’s first SFDA-licensed product, expanding access in the Gulf region.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180859PRIMZONEFULLFEED9722108) on May 18, 2026, and is solely responsible for the information contained therein.